Trial
NCT02472665
Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Grifols Therapeutics LLC
Collaborators
Instituto Grifols, S.A.
Condition
Von Willebrand Disease
Intervention
plasma-derived FVIII/VWF concentrate
Why stopped
Due to recruitment difficulties for pediatric patients. The reason for study cancellation is not related to safety concerns or any adverse events.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-22